STTK
Shattuck Labs, Inc. Healthcare Biotechnology
6/12
Innovation Score
Red Flags (1)
SBC_HIGH (860% of revenue)
Patent Activity
2/3
9 patents found
FUZZY
Cash Runway
2/3
26 months of cash remaining based on current burn rate.
Cash on hand: $90.4M
Cash on hand: $90.4M
Revenue Trajectory
1/3
Revenue: $1.0M
Revenue growth data unavailable.
Revenue growth data unavailable.
Management Quality
1/3
Insider ownership: 38.0%
SBC/Revenue: 860.0%
No reverse splits detected
SBC/Revenue: 860.0%
No reverse splits detected
Key Metrics
Market Cap
$467.8M
Revenue
$1.0M
Revenue Growth (YoY)
N/A
Cash on Hand
$90.4M
Cash Runway
26 months
Shares Outstanding
76.7M
Insider Ownership
38.0%
SBC / Revenue
860.0%
Sector / Industry
Healthcare / Biotechnology
Patents (9)
Match type: FUZZY — company name matched partially; verify assignee
- Heterodimeric proteins and uses thereof
- Fusion proteins for the treatment of cardiometabolic diseases
- Antibodies that bind TNFRSF25
- Heterodimeric proteins for modulating gamma delta T cells
- Fusion proteins for the treatment of cardiometabolic diseases
7-Step Risk Assessment
How STTK maps to our micro cap methodology:
- Innovation Signal 9 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 26 months of runway. Comfortable buffer for execution.
- Revenue Trajectory Revenue data unavailable.
- Management Alignment Insiders hold 38.0% of shares. SBC is 860.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $467.8M company.
Financial Detail
Free Cash Flow
$-22.4M
FCF Yield
-4.8%
Return on Equity
-61.0%
Debt / Equity
3.0%
Gross Margin
-297.8%
Profit Margin
N/A
Operating Margin
-5258.3%
Price / Book
4.69
Current Ratio
22.07
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Quality Flags
Low Debt
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-05-23